A Tale of Two Legacies: Scientific Breakthrough and Legal Scandal at Chinook

The 2023 acquisition of biopharmaceutical firm Chinook Therapeutics by Swiss giant Novartis has culminated in a stark narrative of contrast. Two years later, the deal exemplifies both the pinnacle of medical achievement and a profound breach of legal and ethical standards.

Regulatory Victory and a $3.2 Billion Bet

The scientific promise that drove Novartis to complete its $3.2 billion purchase of Chinook in August 2023 has begun to bear fruit. In a significant development for patients, the U.S. Food and Drug Administration (FDA) granted accelerated approval in April 2025 for the drug Vanrafia. Previously known as atrasentan, this once-daily tablet was a crown jewel in Chinook’s pipeline. Clinical data demonstrated its efficacy in reducing proteinuria—a key marker of kidney damage—by 36.1% in individuals suffering from IgA nephropathy, a progressive kidney disease.

Insider Trading Charges Cast a Shadow

This moment of therapeutic triumph, however, has been severely compromised by allegations of financial misconduct. On May 28, 2025, the U.S. Department of Justice unveiled indictments against five individuals, accusing them of orchestrating an insider trading scheme. Among those charged is a former member of Chinook’s board of directors, Rouzbeh “Ross” Haghighat. The charges allege that the group traded on confidential, non-public information regarding the impending Novartis acquisition, illegally profiting to the tune of more than $600,000.

Should investors sell immediately? Or is it worth buying Chinook Therapeutics?

Implications for Biotech M&A and Investor Trust

These legal proceedings highlight the significant regulatory and governance risks inherent in high-stakes mergers and acquisitions within the volatile biotech sector. While the successful approval of Vanrafia validates the strategic acumen behind Novartis’s acquisition, the concurrent scandal exposes the fragility of trust that underpins multibillion-dollar transactions. It serves as a stark reminder of the legal repercussions that can follow the abuse of privileged information.

Looking forward, Novartis continues to integrate Chinook’s valuable assets and research into its broader nephrology portfolio. Market analysts suggest Vanrafia is positioned to become a major revenue driver in its therapeutic class. For former shareholders of Chinook Therapeutics, the investment story has concluded; the company was delisted following the acquisition, and its shares ceased trading. Any continued financial interest in the drug’s success is now tied directly to the performance of Novartis stock.